Grabar Law Firm Investigating Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After $12.5 Million Class Action Settlement Agreement
Philadelphia, Pa.–(Newsfile Corp. – May 26, 2022) – Odonate Therapeutics Inc. ODT ODTC agreed to pay $12.5 million to resolve a proposed securities class action lawsuit alleging the drug company misled investors about the safety of a new cancer treatment drug. The lawsuit accused the company of making misleading statements and omissions about the development of tesetaxel. The amended complaint alleged that the company and its executives unlawfully inflated the stock price by misleading investors about a clinical trial and the likelihood of FDA approval.
Current Odonate shareholders who have held Odonate shares since at least December 7, 2017 may seek corporate reforms, the return of funds to the company’s coffers and possibly a court-approved incentive award, the optionally.
If you would like to learn more about this matter at no cost to you, please contact us at [email protected] or call 267-507-6085.
These materials have been prepared by Grabar Law Firm for informational purposes only and do not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Previous results mentioned in these documents do not guarantee or suggest a similar result in other areas.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125389